Clinical Trial Update: A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation [Phase 2]

View source ↗

Summary

A Phase II, single-arm trial evaluating the efficacy and safety of Inavolisib in combination with Eribulin in pretreated advanced triple-negative breast cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Eribulin (eribulin mesilate)
• Inavolisib (Inavolisib)

Snippet

Sponsor: Hu Hai | Conditions: TNBC - Triple-Negative Breast Cancer, TNBC | Phase 2 | Status: NOT_YET_RECRUITING